I was surprised to see as much selling pressure today based on the great news we got. I would have thought we'd go and stay above .06 cents at least. I think we still have investors who were part of past financing deals who got shares at lower levels and who sell on days like this when good news is announced. Why would they do that? They may already have sizeable positions in AMBS and they need this portion of their money back. So there still might be an overhang of shares from these kinds of shareholders. Just a theory. For example, I have 1.9 million shares, but I don't intend to keep all of them. I have invested some money that I'll need back in a couple of months. I invested it because I'm speculating it will double or triple. I'll probably only be able to keep 1.6 million of the 1.9. Everyone has their own circumstances like this, so some selling on big days from these kind of people is normal
But I think news like todays is pouring gasoline on the stack of wood. But we still need a match to light it up!! That match or spark is MONEY. This is what Jason Napodano has been saying about us for months. Our value should be north of .20 cents, but we have to make our financials stronger. If we get one or more catalysts that get us above .10 cents for 20 days and we get the 5 million, that will help. But we probably need a little more. Maybe that is where BD comes in with some kind of upfront money for LymPro, even if it is only 10 million with future milestone payments. Once our cash picture improves...the stock could quite easily go above .20 to .30 cents.
The Jack and JT Snow Foundation have made a video about Wolfram's Syndrome which Regis Philben narrates. It features clips from Dr. Urano, mentioned in the PR this morning. They talk about the fact that finding a cure for Wolframs is essentially the same as finding a cure for Type 2 Diabetes. It is only an 11 minute video, but you definitely need to watch it. They don't mention the name of the drug they believe is "on the 1 yard line" for curing Wolframs, but after today's PR we all know that drug to be MANF. Some of us, of course, knew it prior to today. Just Google "Snow Foundation Wolframs Video"
quintilien: Excellent comment. I agree, you should sell your shares this morning! You don't deserve to have any more "remorse" over your purchase of AMBS. Good bye!
Gerald told me in LA two weeks ago that there would be a lot of news in the next two months. This was merely the first piece of news. I suspect the MMs are holding us back because they know more news is coming and they don't want the stock to shoot up too fast. We've had over 3.3 million shares trade in the first 30 minutes. Who is selling shares down at 5.5 cents after this news? Market Makers. That's what they do. I don't think true shorts are holding us back. By mid February the stock price will be well north of .15 cents but Market Makers like to do things in an orderly way. Each piece of news will build on the other. We'll start attracting new shareholders. Most of us old ones have already mortgaged the home, so we need to get the word out about Wolframs/Diabetes and the stock should do nicely over the holidays. But I think this is just the beginning of news releases.
Yes, Bigbang mentioned it too! But he is on a sabbatical to Tasmania and can't be reached. Perhaps Coldcoffee can get a message to him? If he can, what I'd like to know is: When will our stock price reach $15? By April of 2014 or September of 2014? I need to know. There is some beach front property in Malibu I am looking at next to Goldie Hawn and Kurt Russell. It's valued at over 10 million and I was wondering if I should make an offer. Coldcoffee, can you get through to Bigbang? Tell him I need to know cause its a really hot property!!
Gerald referred to Janssen Labs as a "storefront" for them to display their pipeline to Big Pharma and Venture Capitalists who frequently come by the Lab to see what new and innovative things are available to invest in. Well, right now AMBS has two new orphan indications for MANF: Retinitis and Wolframs/Diabetes. Because they are orphans, the time and money required by the FDA is substantially reduced. And, with both of these indications, their label can be expanded dramatically once they receive FDA approval. For Wolframs that means we can begin treating Type 2 Diabetes. Dr. Urano said "Finding a cure for Wolframs is finding a cure for Type 2 Diabetes." That is huge! But I don't expect Gerald to announce a partnership anytime soon on either of these two orphans. We might be able to do them ourselves due to all the loans and grants made available by the Government and other agencies for orphans. But, Gerald will proudly display them in his "storefront" window at Janssen's Labs, along side all the other MANF indications he'll be adding. I suspect some Big Pharma is going to have to pay us a load of money to get a partnership deal on either orphan. Maybe there will be a bidding war?
Well we have to give credit where credit is due. Watsonhelper predicted we would announce huge news on Diabetes a few months ago and at first I didn't believe him. However, on both of my face to face visits with Gerald I have had conversations with him that led me to believe Watson was right. I have acknowledged this before on the mb. However, Watson said AMBS would announce a "Diagnostic" deal before December Two Zero and just yesterday I poked fun at him because it appeared time was running out on his prediction. Well, well, well...Amarantus is going to have a nice run here in the next several weeks and months. Too bad Watson made his final post. Perhaps this news will draw him back for a little: I TOLD YOU SO!!
$1 dollar by mid February would be nice, but I'm thinking .15 to .40 cents as a reasonable expectation. All the stars would have to align to get us to $1 by then. It is possible though; multiple partnerships!!
I hope you don't expire over the holidays because I doubt they'll be announcing any blockbuster news the week before Christmas.
Watson predicted a diagnostic announcement before December Two Zero. I don't think any of his predictions have come true yet. At least everyone knew when Bigbang said he was going to Tasmania on a sabbatical, he was merely switching to a new alias: Coldcoffee. I think Watson got tired of going out on a limb making projections...only to have his tree cut down each time. Oh well.
Gerald was a football player, true, but as a boy it was his working in the lab with his father (a biomedical genius) that is Gerald's greatest credential!
Janssen Labs "invited" Amarantus to join their facility after a careful screening process. Janssen requires that they companies they invite be financially solid and have incredible potential with what they are working on. I suspect Janssen Labs (Johnson & Johnson) know more about what Gerald is sitting on that the shorts do. The shorts seem to think Amarantus has no significant value, but Janssen Labs disagrees. They probably know what gave Gerald the confidence to structure the last financing deal the way he did, where we have to be above .10 cents for 20 days to get the 5 million dollars from warrants. That is why they invited us in. Do the shorts know what Gerald is sitting on? Probably. Why are they then shorting us in this fashion? Timing. They think they are smart enough to steal shares away from weak longs before Gerald announces the news he is sitting on. If their timing is right, they will make money going down, cover their short position, and make money on the ride back up. When short trader's timing is good they make big money. When their timing is off, If Gerald were to pull a December surprise with big news, THE SHORTS GET KILLED! We'll all see how predictable Gerald is, and how smart shorts turn out to be. Trust me, they won't be shorting the stock coming mid January. If Helperwatson is right about a major announcement before December "Two Zero," we could see short's nuts roosting on an open fire!!
Small Bio-Med Stocks with lots of promise are fertile ground for short traders. Why? Because people buy in at early stages in a company based on that company's promising pipeline. Excitement builds and speculators lift the stock price for a time, but inevitably there is not enough news or revenue in those early preclinical stages to sustain it and the stock price goes right back down, aided by seasoned short sellers.
Are all small Bio-Med stocks doomed? Mostly. Do some ever make it beyond this frustrating paradigm? Yes, Amgen is a prime example of a small penny stock Bio-Med that made it big. There are others. What are the signs that indicate a small Bio-Med will succeed? Read up on Amarantus Biosciences, the signs are all there!
What happens to the shorts when a small company breaks through? Watch and learn.
I think someone is defending the stock from shorts. Maybe a large shareholder who doesn't really want more shares but is willing to draw a line in the sand at .047 or so? Just a thought.
Merry Christmas cheesdweeb, the funding for TBI is going to come to AMBS from OneMind & the NFL within the next 60 days!! That's why we're making such a big deal at the UN on Super Bowl week. And that is why we were invited to Janssen Labs because they and UCSF are specialists in TBI. This is going to be good for us.
Amarantus really hasn't even begun their Business Model yet, which is TO LICENSE OFF MANF ORPHANS & INDICATIONS FOR LARGE UPFRONT MONEY AND FUTURE MILESTONE PAYMENTS AND ROYALTIES, but they're about to start. The first group of candidates include: TBI, Wolframs/Diabetes, Retinitis, Parkinsons, & Ischemic Heart. Some of these might get deals done in the next couple of months. Some might take 6 months or a year. But the REVENUE in the form of Licensing Payments is about to start. What is unique about Amarantus and MANF is that the number of indications possible from this one drug is astonishing! Will there be 10, 20, or 30 indications coming from MANF? We know that indications for Hearing, Strokes, and Organ Transplants have been briefly mentioned. Certainly we will hear more about them and others as our Business Model ramps up. As we start scoring some large upfront money we'll have the ability to bring these other indications along...giving us a continual stream of Licensing Revenue. We'll be getting first time Licensing deals in two years that will be in addition to milestone payments received from prior licensing deals. With 5 or 6 licensing deals in the next 2 years our revenue is going to start growing geometrically, especially as the LymPro revenues ramp in 2015 and 2016. And, being in Janseen Labs gives us the perfect showcase to execute this Business Model!! They call it an INCUBATOR for a reason: it speeds up growth for young promising companies....like AMBS! Once we score our first deal the shorts will back off because they know we have several other licensing deals waiting in the wings. I expect to hear about our first deal very soon!
No doubt some funding will come to us from either the NFL, the Government, or groups like OneMind, which Johnson & Johnson is a part of. MANF's indication for TBI plus LymPro's new potential to diagnose TBI will garner a lot of attention in January and February. It should move our pps up considerably!